Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1864298rdf:typepubmed:Citationlld:pubmed
pubmed-article:1864298lifeskim:mentionsumls-concept:C0085393lld:lifeskim
pubmed-article:1864298lifeskim:mentionsumls-concept:C0034428lld:lifeskim
pubmed-article:1864298lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:1864298pubmed:issue4lld:pubmed
pubmed-article:1864298pubmed:dateCreated1991-9-12lld:pubmed
pubmed-article:1864298pubmed:abstractTextImmune deficiency generally leads to infections. Cancer chemotherapy, medical interventions and various investigational procedures are important factors in the development of infection. In recent decades, there has been a major change in most cancer centers in the etiology of bacterial infections occurring in the immunocompromised host, most infections now being caused by gram-positive organisms. This might be partly due to prophylactic use of agents effective against gram-negative bacteria. The quinolones are now widely used in the treatment of serious infections of the immunocompromised patient. Prophylaxis with quinolones is also practised in cancer centers.lld:pubmed
pubmed-article:1864298pubmed:languageenglld:pubmed
pubmed-article:1864298pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1864298pubmed:citationSubsetIMlld:pubmed
pubmed-article:1864298pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1864298pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1864298pubmed:statusMEDLINElld:pubmed
pubmed-article:1864298pubmed:monthAprlld:pubmed
pubmed-article:1864298pubmed:issn0934-9723lld:pubmed
pubmed-article:1864298pubmed:authorpubmed-author:MaicheA GAGlld:pubmed
pubmed-article:1864298pubmed:issnTypePrintlld:pubmed
pubmed-article:1864298pubmed:volume10lld:pubmed
pubmed-article:1864298pubmed:ownerNLMlld:pubmed
pubmed-article:1864298pubmed:authorsCompleteYlld:pubmed
pubmed-article:1864298pubmed:pagination361-7lld:pubmed
pubmed-article:1864298pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1864298pubmed:meshHeadingpubmed-meshheading:1864298-...lld:pubmed
pubmed-article:1864298pubmed:meshHeadingpubmed-meshheading:1864298-...lld:pubmed
pubmed-article:1864298pubmed:meshHeadingpubmed-meshheading:1864298-...lld:pubmed
pubmed-article:1864298pubmed:meshHeadingpubmed-meshheading:1864298-...lld:pubmed
pubmed-article:1864298pubmed:meshHeadingpubmed-meshheading:1864298-...lld:pubmed
pubmed-article:1864298pubmed:meshHeadingpubmed-meshheading:1864298-...lld:pubmed
pubmed-article:1864298pubmed:meshHeadingpubmed-meshheading:1864298-...lld:pubmed
pubmed-article:1864298pubmed:meshHeadingpubmed-meshheading:1864298-...lld:pubmed
pubmed-article:1864298pubmed:meshHeadingpubmed-meshheading:1864298-...lld:pubmed
pubmed-article:1864298pubmed:meshHeadingpubmed-meshheading:1864298-...lld:pubmed
pubmed-article:1864298pubmed:year1991lld:pubmed
pubmed-article:1864298pubmed:articleTitleUse of quinolones in the immunocompromised host.lld:pubmed
pubmed-article:1864298pubmed:affiliationDepartment of Radiotherapy and Oncology, Helsinki University Central Hospital, Finland.lld:pubmed
pubmed-article:1864298pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1864298pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1864298pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1864298lld:pubmed